Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392258 | 0.87 | CTPS1 (0.57) | CTPS1SCN9A | |
| SCHEMBL21381503 | 0.83 | CTPS1 (0.48) | CTPS1 | |
| SCHEMBL22924884 | 0.80 | CTPS1 (0.61) | CTPS1 | |
| SCHEMBL6418756 | 0.77 | KCNH2 (0.43) | CTPS1 | |
| SCHEMBL21044216 | 0.76 | CTPS1 (0.46) | CTPS1 | |
| SCHEMBL31152528 | 0.75 | CTPS1 (1.00) | CTPS1 | |
| SCHEMBL21392234 | 0.73 | CTPS1 (0.59) | CTPS1SCN9A | |
| SCHEMBL17868449 | 0.73 | KDM4E (0.50) | CTPS1SCN9A | |
| SCHEMBL21392233 | 0.73 | CTPS1 (0.64) | CTPS1SCN9A | |
| SCHEMBL30528826 | 0.73 | CTPS1 (0.85) | CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885SCN9A 1275/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885SCN9A 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.